Ferroptosis-Mediated Inflammation Promotes Pulmonary Hypertension
Top Cited Papers
- 8 November 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 135 (11) , 1067-1083
Abstract
BACKGROUND: Mitochondrial dysfunction, characterized by impaired lipid metabolism and heightened reactive oxygen species generation, results in lipid peroxidation and ferroptosis. Ferroptosis is an inflammatory mode of cell death that promotes complement activation and macrophage recruitment. In pulmonary arterial hypertension (PAH), pulmonary arterial endothelial cells exhibit cellular phenotypes that promote ferroptosis. Moreover, there is ectopic complement deposition and inflammatory macrophage accumulation in the pulmonary vasculature. However, the effects of ferroptosis inhibition on these pathogenic mechanisms and the cellular landscape of the pulmonary vasculature are incompletely defined. METHODS: Multiomics and physiological analyses evaluated how ferroptosis inhibition–modulated preclinical PAH. The impact of adeno-associated virus 1–mediated expression of the proferroptotic protein ACSL (acyl-CoA synthetase long-chain family member) 4 on PAH was determined, and a genetic association study in humans further probed the relationship between ferroptosis and pulmonary hypertension. RESULTS: Ferrostatin-1, a small-molecule ferroptosis inhibitor, mitigated PAH severity in monocrotaline rats. RNA-sequencing and proteomics analyses demonstrated ferroptosis was associated with PAH severity. RNA-sequencing, proteomics, and confocal microscopy revealed complement activation and proinflammatory cytokines/chemokines were suppressed by ferrostatin-1. In addition, ferrostatin-1 combatted changes in endothelial, smooth muscle, and interstitial macrophage abundance and gene activation patterns as revealed by deconvolution RNA-sequencing. Ferroptotic pulmonary arterial endothelial cell damage–associated molecular patterns restructured the transcriptomic signature and mitochondrial morphology, promoted the proliferation of pulmonary artery smooth muscle cells, and created a proinflammatory phenotype in monocytes in vitro. Adeno-associated virus 1- Acsl4 induced an inflammatory PAH phenotype in rats. Finally, single-nucleotide polymorphisms in 6 ferroptosis genes identified a potential link between ferroptosis and pulmonary hypertension severity in the Vanderbilt BioVU repository. CONCLUSIONS: Ferroptosis promotes PAH through metabolic and inflammatory mechanisms in the pulmonary vasculature.Keywords
This publication has 61 references indexed in Scilit:
- Ferrostatin-1 Blunts Right Ventricular Hypertrophy and Dysfunction in Pulmonary Arterial Hypertension by Suppressing the HMOX1/GSH SignalingJournal of Cardiovascular Translational Research, 2023
- Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applicationsCell, 2022
- Iron Deficiency Is Associated With More Severe Pulmonary Vascular Disease in Pulmonary Hypertension Caused by Chronic Lung DiseaseChest, 2022
- The emerging role of ferroptosis in inflammationBiomedicine & Pharmacotherapy, 2020
- Transferrin Receptor Is a Specific Ferroptosis MarkerCell Reports, 2020
- A simple ImageJ macro tool for analyzing mitochondrial network morphology in mammalian cell cultureActa Histochemica, 2017
- The Metabolic Basis of Pulmonary Arterial HypertensionCell Metabolism, 2014
- Iron chelation inhibits the development of pulmonary vascular remodelingFree Radical Biology and Medicine, 2012
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012
- VE‐Cadherin‐Cre‐recombinase transgenic mouse: A tool for lineage analysis and gene deletion in endothelial cellsDevelopmental Dynamics, 2006